Proteome Sciences Refines Assays For Early Alzheimer's Detection
Executive Summary
Proteome Sciences' diagnostic technologies are showing promise in detecting the onset of Alzheimer's disease earlier than any other method according to data from ongoing clinical trials presented at the recent Alzheimer’s Association International Conference (AAIC) in Washington, July 18-23.
You may also be interested in...
Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty
With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.